转移性肝癌介入治疗的疗效及影响预后的因素

THE THERAPEUTIC EFFECT OF INTERVENTION THERAPY TO METASTATIC LIVER CANCER AND THE FACTORS AFFECTING THE PROGNOSIS

目的探讨转移性肝癌介入治疗的疗效及影响预后的因素。方法36例中，原发癌灶切除者17例，未切除者19例；肝动脉化疗栓塞治疗19例，肝动脉化疗药物灌注治疗者17例。结果原发癌灶切除组半年生存率（76．5％），较未切除者（36．8％）具有显著性差异（P＜0．05）。肝动脉化疗栓塞治疗组半年生存率（78．9％），较肝动脉化疗药物灌注治疗组（29．4％）具有高度显著性差异（P＜0．01）。结论转移性肝癌患者，应尽可能切除原发癌灶，并给全身化疗，免疫治疗及原发癌灶的选择性动脉化疗药物灌注治疗或放疗等综合治疗。一般情况好，肝功能基本正常，无黄疸及门静脉主干癌栓形成的转移性肝癌患者，应行肝动脉化疗栓塞治疗，以延长患者的生存期。

To explore the therapeutic effect of intervention therapy on metastatic liver cancer and the factors affecting the prognosis. Methods Setting up 36 cases,among them: 17 cases had their primary cancer resected, 19 cases had not; 19cases had been treated with hepatic artery chemotherapy embolism, 17 cases had been perfused with chemotherapy medicines in hepatic artery. Results The half a year survival rate of the group with primary cancer-foci resected was 78. 9 %. There was apparentdifference (P<0. 05)compared with that of the group without resection (36. 8 % ). The half a year survival rate of the group treatedwith hepatic artery chemotherapy embolism was 78. 9%. There was much apparent difference (P<0. 01)compared with that of thegroup perfused with chemotherapy medicines in hepatic artery Conclusion To the patients with metastatic liver cancer,their primary cancer-foci should be resected as soon as possible and combined treatment should be given such as whole-body chemotherapy,immunologic therapy and the therapy of perfusing selective artery chemotherapy medicines to primary cancer-foci or radiotherapy. If their general conditions are good,their liver function basically normal,and they have no jaundice and no cancer-embolismformed in main body of portal vein,they should be given the therapy of liver artery chemotherapy embolism to prolong their survival duration.